Skip to main content
Top
Published in: Digestive Diseases and Sciences 3/2015

01-03-2015 | Review

Multi-Target Stool DNA Test: A New High Bar for Noninvasive Screening

Author: David A. Ahlquist

Published in: Digestive Diseases and Sciences | Issue 3/2015

Login to get access

Abstract

Stool DNA testing has evolved into what is now a highly accurate and well-validated test for the screen detection of colorectal neoplasia. An optimized and automated multi-target stool DNA test (MT-sDNA) has achieved the same high point-sensitivities as reported for colonoscopy and significantly higher sensitivity than by fecal immunochemical blood testing for detection of early-stage cancer and advanced precancer. Thus, MT-sDNA sets a new high criterion standard for the noninvasive screen detection of colorectal neoplasia. With clinical application, MT-sDNA has potential to meaningfully address current gaps in our approach to CRC screening through benefits of its high accuracy on screening effectiveness, user-friendly features on patient compliance, and easy mail-out distribution on test access. The US Food and Drug Administration and Center for Medicaid and Medicare Services have recently completed their parallel reviews of MT-sDNA, which has just become available for clinical use. This review summarizes the recent clinical validation data on MT-sDNA, addresses central clinical questions at this front end of implementation, and touches on innovative future applications of stool DNA testing.
Literature
1.
go back to reference Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science. 1992;256:102–105.CrossRefPubMed Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science. 1992;256:102–105.CrossRefPubMed
2.
go back to reference Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology. 2000;119:1219–1227.CrossRefPubMed Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology. 2000;119:1219–1227.CrossRefPubMed
3.
go back to reference Dong SM, Traverso G, Johnson C, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst. 2001;93:858–865.CrossRefPubMed Dong SM, Traverso G, Johnson C, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst. 2001;93:858–865.CrossRefPubMed
4.
go back to reference Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370:1287–1297.CrossRefPubMed Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370:1287–1297.CrossRefPubMed
5.
go back to reference Bressler B, Paszat LF, Vinden C, Li C, et al. Colonoscopic miss rates for right-sided colon cancer: a population-based analysis. Gastroenterology. 2004;127:452–456.CrossRefPubMed Bressler B, Paszat LF, Vinden C, Li C, et al. Colonoscopic miss rates for right-sided colon cancer: a population-based analysis. Gastroenterology. 2004;127:452–456.CrossRefPubMed
6.
go back to reference Patel SG, Ahnen DJ. Prevention of interval colorectal cancers: what every clinician needs to know. Clin Gastroenterol Hepatol. 2014;12:7–15.CrossRefPubMed Patel SG, Ahnen DJ. Prevention of interval colorectal cancers: what every clinician needs to know. Clin Gastroenterol Hepatol. 2014;12:7–15.CrossRefPubMed
7.
go back to reference Cooper GS, Xu F, Barnholtz Sloan JS, et al. Prevalence and predictors of interval colorectal cancers in medicare beneficiaries. Cancer. 2012;118:3044–3052.CrossRefPubMedCentralPubMed Cooper GS, Xu F, Barnholtz Sloan JS, et al. Prevalence and predictors of interval colorectal cancers in medicare beneficiaries. Cancer. 2012;118:3044–3052.CrossRefPubMedCentralPubMed
8.
go back to reference Singh H, Nugent Z, Mahmud SM, et al. Predictors of colorectal cancer after negative colonoscopy: a population-based study. Am J Gastroenterol. 2010;105:663–673.CrossRefPubMed Singh H, Nugent Z, Mahmud SM, et al. Predictors of colorectal cancer after negative colonoscopy: a population-based study. Am J Gastroenterol. 2010;105:663–673.CrossRefPubMed
9.
go back to reference Samadder NJ, Curtin K, Tuohy TMF, et al. Characteristics of missed or interval colorectal cancer and patient survival: a population-based study. Gastroenterology. 2014;146:950–960.CrossRefPubMed Samadder NJ, Curtin K, Tuohy TMF, et al. Characteristics of missed or interval colorectal cancer and patient survival: a population-based study. Gastroenterology. 2014;146:950–960.CrossRefPubMed
10.
go back to reference Lidgard GP, Dominco M, Bruinsma JJ, Gagrat ZD, Oldham-Haltom RL, et al. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. Clin Gastroenterol Hepatol. 2013;11:1313–1318.CrossRefPubMed Lidgard GP, Dominco M, Bruinsma JJ, Gagrat ZD, Oldham-Haltom RL, et al. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. Clin Gastroenterol Hepatol. 2013;11:1313–1318.CrossRefPubMed
11.
go back to reference Ahlquist DA, Harrington JJ, Burgart LJ, Roche PC. Morphometric analysis of the “mucocellular layer” overlying colorectal cancer and normal mucosa: relevance to exfoliation and stool screening. Hum Pathol. 2000;31:51–57.CrossRefPubMed Ahlquist DA, Harrington JJ, Burgart LJ, Roche PC. Morphometric analysis of the “mucocellular layer” overlying colorectal cancer and normal mucosa: relevance to exfoliation and stool screening. Hum Pathol. 2000;31:51–57.CrossRefPubMed
12.
go back to reference Berger BM, Ahlquist DA. Stool DNA screening for colorectal neoplasia: biological and technical basis for high detection rates. Pathology. 2012;44:80–88.CrossRefPubMed Berger BM, Ahlquist DA. Stool DNA screening for colorectal neoplasia: biological and technical basis for high detection rates. Pathology. 2012;44:80–88.CrossRefPubMed
13.
14.
go back to reference Zou H, Taylor WR, Harrington JJ, et al. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology. 2009;136:459–470.CrossRefPubMed Zou H, Taylor WR, Harrington JJ, et al. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology. 2009;136:459–470.CrossRefPubMed
15.
go back to reference Diehl F, Schmidt K, Durkee KH, et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology. 2008;135:489–498.CrossRefPubMedCentralPubMed Diehl F, Schmidt K, Durkee KH, et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology. 2008;135:489–498.CrossRefPubMedCentralPubMed
16.
go back to reference Boynton KA, Summerhayes IC, Ahlquist DA, Shuber AP. DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem. 2003;49:1058–1065.CrossRefPubMed Boynton KA, Summerhayes IC, Ahlquist DA, Shuber AP. DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem. 2003;49:1058–1065.CrossRefPubMed
17.
go back to reference Zou H, Harrington JJ, Klatt KK, Ahlquist DA. A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screening. Cancer Epidemiol Biomarkers Prev. 2006;15:1115–1119.CrossRefPubMed Zou H, Harrington JJ, Klatt KK, Ahlquist DA. A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screening. Cancer Epidemiol Biomarkers Prev. 2006;15:1115–1119.CrossRefPubMed
18.
go back to reference Ahlquist DA, Zou H, Domanico M, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology. 2012;142:248–56; quiz e25–e26. Ahlquist DA, Zou H, Domanico M, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology. 2012;142:248–56; quiz e25–e26.
19.
go back to reference Kisiel JB, Ahlquist DA. Stool DNA screening for colorectal cancer: opportunities to improve value with next generation tests. J Clin Gastroenterol. 2010;45:301–308.CrossRef Kisiel JB, Ahlquist DA. Stool DNA screening for colorectal cancer: opportunities to improve value with next generation tests. J Clin Gastroenterol. 2010;45:301–308.CrossRef
20.
go back to reference Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology. 2005;129:422–428.CrossRefPubMed Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology. 2005;129:422–428.CrossRefPubMed
21.
go back to reference Ahlquist DA, Sargent DJ, Loprinzi CL, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008;149:441–450, W81. Ahlquist DA, Sargent DJ, Loprinzi CL, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008;149:441–450, W81.
22.
go back to reference Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375:1624–1633.CrossRefPubMed Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375:1624–1633.CrossRefPubMed
23.
go back to reference Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012;366:2345–2357.CrossRefPubMedCentralPubMed Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012;366:2345–2357.CrossRefPubMedCentralPubMed
24.
go back to reference Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann Intern Med. 2009;150:1–8.CrossRefPubMed Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann Intern Med. 2009;150:1–8.CrossRefPubMed
25.
go back to reference Brenner H, Hoffmeister M, Arndt V, Stegmaier C, Altenhofen L, Haug U. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J Natl Cancer Inst. 2010;102:89–95.CrossRefPubMed Brenner H, Hoffmeister M, Arndt V, Stegmaier C, Altenhofen L, Haug U. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J Natl Cancer Inst. 2010;102:89–95.CrossRefPubMed
26.
go back to reference Nishihara R, Wu K, Lochhead MB, Morikawa T, et al. Long-term colorectal cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013;369:1095–1105.CrossRefPubMed Nishihara R, Wu K, Lochhead MB, Morikawa T, et al. Long-term colorectal cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013;369:1095–1105.CrossRefPubMed
27.
go back to reference Berger BM, Imperiale T, Hilsden R, Sutter A, et al. Noninvasive detection of sessile serrated polyps in an average risk colorectal cancer screening population: comparison of stool-based multi-target DNA and fecal immunochemical testing. Gastroenterology. 2014;146:S-31. Berger BM, Imperiale T, Hilsden R, Sutter A, et al. Noninvasive detection of sessile serrated polyps in an average risk colorectal cancer screening population: comparison of stool-based multi-target DNA and fecal immunochemical testing. Gastroenterology. 2014;146:S-31.
28.
go back to reference Redwood D, Esay A, Sacco P, Christensen C, et al. Stool DNA testing for screen-detection of colorectal neoplasia in Alaska native people. Gastroenterology. 2014;146:S-403. Redwood D, Esay A, Sacco P, Christensen C, et al. Stool DNA testing for screen-detection of colorectal neoplasia in Alaska native people. Gastroenterology. 2014;146:S-403.
29.
go back to reference Lieberman DA, Ransohoff D, Winawer SJ, Giardello FM, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US multi-society task force on colorectal cancer. Gastroenterology. 2012;143:844–857.CrossRefPubMed Lieberman DA, Ransohoff D, Winawer SJ, Giardello FM, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US multi-society task force on colorectal cancer. Gastroenterology. 2012;143:844–857.CrossRefPubMed
30.
go back to reference Kozarek RA, Botoman VA, Bredfeldt JE, Roach JM, Patterson DJ, Ball TJ. Portal colopathy: prospective study of colonoscopy in patients with portal hypertension. Gastroenterology. 1991;101:1192–1197.PubMed Kozarek RA, Botoman VA, Bredfeldt JE, Roach JM, Patterson DJ, Ball TJ. Portal colopathy: prospective study of colonoscopy in patients with portal hypertension. Gastroenterology. 1991;101:1192–1197.PubMed
31.
go back to reference Allison JE, Meijer G. Colonic polyps: the harm of overdiagnosis. Pract Gastroenterol. 2012:25–38. Allison JE, Meijer G. Colonic polyps: the harm of overdiagnosis. Pract Gastroenterol. 2012:25–38.
32.
go back to reference Stryker SJ, Wolff BG, Culp CE, Libbe SD, Ilstrup DM, MacCarty RL. Natural history of untreated colonic polyps. Gastroenterology. 1987;93:1009–1013.PubMed Stryker SJ, Wolff BG, Culp CE, Libbe SD, Ilstrup DM, MacCarty RL. Natural history of untreated colonic polyps. Gastroenterology. 1987;93:1009–1013.PubMed
33.
go back to reference Pickhardt PJ. The natural history of colorectal polyps and masses: rediscovered truths from the barium enema era. Am J Radiol. 2007;188:619–621. Pickhardt PJ. The natural history of colorectal polyps and masses: rediscovered truths from the barium enema era. Am J Radiol. 2007;188:619–621.
34.
go back to reference Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525–532.CrossRefPubMed Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525–532.CrossRefPubMed
35.
go back to reference Rubio CA. Qualitative DNA differences between two structurally different lesions: high-grade dysplasia and carcinoma in situ in colorectal adenomas. Anticancer Res. 2007;27:2881–2886.PubMed Rubio CA. Qualitative DNA differences between two structurally different lesions: high-grade dysplasia and carcinoma in situ in colorectal adenomas. Anticancer Res. 2007;27:2881–2886.PubMed
36.
go back to reference Rubio CA, Delinassios JG. Invasive carcinomas may arise in colorectal adenomas with high-grade dysplasia and with carcinoma in situ. Int J Clin Exp Med. 2010;3:41–47.PubMedCentralPubMed Rubio CA, Delinassios JG. Invasive carcinomas may arise in colorectal adenomas with high-grade dysplasia and with carcinoma in situ. Int J Clin Exp Med. 2010;3:41–47.PubMedCentralPubMed
37.
go back to reference Toll AD, Fabius D, Hyslop T, Pequignot E, et al. Prognostic significance of high-grade dysplasia in colorectal adenomas. Colorectal Dis. 2011;13:370–373.CrossRefPubMed Toll AD, Fabius D, Hyslop T, Pequignot E, et al. Prognostic significance of high-grade dysplasia in colorectal adenomas. Colorectal Dis. 2011;13:370–373.CrossRefPubMed
38.
go back to reference Sheridan TB, Fenton H, Lewin MR, et al. Sessile serrated adenomas with low- and high-grade dysplasia and early carcinomas: an immunohistochemical study of serrated lesions “caught in the act”. Am J Clin Pathol. 2006;126:564–571.CrossRefPubMed Sheridan TB, Fenton H, Lewin MR, et al. Sessile serrated adenomas with low- and high-grade dysplasia and early carcinomas: an immunohistochemical study of serrated lesions “caught in the act”. Am J Clin Pathol. 2006;126:564–571.CrossRefPubMed
39.
go back to reference Pickhardt PJ, Hain KS, Kim DH, Hassan C. Low rates of cancer or high-grade dysplasia in colorectal polyps collected from computed tomography colonography screening. Clin Gastroenterol Hepatol. 2010;8:610–615.CrossRefPubMed Pickhardt PJ, Hain KS, Kim DH, Hassan C. Low rates of cancer or high-grade dysplasia in colorectal polyps collected from computed tomography colonography screening. Clin Gastroenterol Hepatol. 2010;8:610–615.CrossRefPubMed
40.
go back to reference Bozic I, Antal T, Ohtsuk H, Carter H, et al. Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci USA. 2010;107:18545–18550.CrossRefPubMedCentralPubMed Bozic I, Antal T, Ohtsuk H, Carter H, et al. Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci USA. 2010;107:18545–18550.CrossRefPubMedCentralPubMed
41.
go back to reference Ahlquist DA, Taylor WR, Yab TC, et al. Aberrantly methylated gene marker levels in stool: effects of demographic, exposure, body mass, and other patient characteristics. J Mol Biomark Diagn. 2012;3:1–7. Ahlquist DA, Taylor WR, Yab TC, et al. Aberrantly methylated gene marker levels in stool: effects of demographic, exposure, body mass, and other patient characteristics. J Mol Biomark Diagn. 2012;3:1–7.
42.
go back to reference Zou HJ, Hussain FT, Cao X, et al. Stool DNA and occult blood for detection of colorectal cancer: complementary markers. Gastroenterology. 2009;136:A625.CrossRef Zou HJ, Hussain FT, Cao X, et al. Stool DNA and occult blood for detection of colorectal cancer: complementary markers. Gastroenterology. 2009;136:A625.CrossRef
43.
go back to reference Heigh RI, Yab TC, Taylor WR, Hussain FT, Smyrk TC, et al. Detection of colorectal serrated polyps by stool DNA testing: comparison with fecal immunochemical testing for occult blood (FIT). PLoS ONE. 2014;9:e85659.CrossRefPubMedCentralPubMed Heigh RI, Yab TC, Taylor WR, Hussain FT, Smyrk TC, et al. Detection of colorectal serrated polyps by stool DNA testing: comparison with fecal immunochemical testing for occult blood (FIT). PLoS ONE. 2014;9:e85659.CrossRefPubMedCentralPubMed
44.
go back to reference Grutzmann R, Molnar B, Pilarsky C, et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS ONE. 2008;3:e3759.CrossRefPubMedCentralPubMed Grutzmann R, Molnar B, Pilarsky C, et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS ONE. 2008;3:e3759.CrossRefPubMedCentralPubMed
45.
go back to reference deVos T, Tetzner R, Model F, et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin. Chem.. 2009;55:1337–1346.CrossRefPubMed deVos T, Tetzner R, Model F, et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin. Chem.. 2009;55:1337–1346.CrossRefPubMed
46.
go back to reference Tanzer M, Balluff B, Distler J, et al. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS ONE. 2010;5:e9061.CrossRefPubMedCentralPubMed Tanzer M, Balluff B, Distler J, et al. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS ONE. 2010;5:e9061.CrossRefPubMedCentralPubMed
47.
go back to reference Church TRWM, Lofton-Day C, Mongin S, Blumenstein BA, et al. Prospective clinical validation of an assay for methylated SEPT9 DNA in human plasma as a colorectal cancer screening tool in average risk men and women ≥50 years (abstract). Gastroenterology. 2010;130:e18.CrossRef Church TRWM, Lofton-Day C, Mongin S, Blumenstein BA, et al. Prospective clinical validation of an assay for methylated SEPT9 DNA in human plasma as a colorectal cancer screening tool in average risk men and women ≥50 years (abstract). Gastroenterology. 2010;130:e18.CrossRef
48.
go back to reference DA Ahlquist TW, Mahoney DW, Zou H, Domanico M, et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin Gastroenterol Hepatol. 2012;10:272–277.CrossRefPubMedCentralPubMed DA Ahlquist TW, Mahoney DW, Zou H, Domanico M, et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin Gastroenterol Hepatol. 2012;10:272–277.CrossRefPubMedCentralPubMed
49.
go back to reference Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63:317–325.PubMedCentralPubMed Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63:317–325.PubMedCentralPubMed
50.
go back to reference Brenner H, Chang-Claude J, Seiler CM, Rickert A, Hoffmeister M. Protection from colorectal cancer after colonoscopy: a population-based, case–control study. Ann Intern Med. 2011;154:22–30.CrossRefPubMed Brenner H, Chang-Claude J, Seiler CM, Rickert A, Hoffmeister M. Protection from colorectal cancer after colonoscopy: a population-based, case–control study. Ann Intern Med. 2011;154:22–30.CrossRefPubMed
51.
go back to reference Sawhney MS, Farrar W, Gudiseva S, et al. Microsatellite instability in interval colon cancers. Gastroenterology. 2006;131:1700–1705.CrossRefPubMed Sawhney MS, Farrar W, Gudiseva S, et al. Microsatellite instability in interval colon cancers. Gastroenterology. 2006;131:1700–1705.CrossRefPubMed
52.
go back to reference Imperiale TF, Eckert G, Juliar BE, Azzouz F, Ransohoff DF. Prevalence and variable detection of proximal colon serrated polyps during screening colonoscopy. Gastrointest Endosc. 2009;69:1288–1295.CrossRefPubMed Imperiale TF, Eckert G, Juliar BE, Azzouz F, Ransohoff DF. Prevalence and variable detection of proximal colon serrated polyps during screening colonoscopy. Gastrointest Endosc. 2009;69:1288–1295.CrossRefPubMed
53.
go back to reference Pickhardt PJ, Choi JR, Hwang I, et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med. 2003;349:2191–2200.CrossRefPubMed Pickhardt PJ, Choi JR, Hwang I, et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med. 2003;349:2191–2200.CrossRefPubMed
54.
go back to reference Kahi CJ, Hewett DG, Norton DL, Eckert GJ, Rex DK. Prevalence and variable detection of proximal colon serrated polyps during screening colonoscopy. Clin Gastroenterol Hepatol. 2011;9:42–46.CrossRefPubMed Kahi CJ, Hewett DG, Norton DL, Eckert GJ, Rex DK. Prevalence and variable detection of proximal colon serrated polyps during screening colonoscopy. Clin Gastroenterol Hepatol. 2011;9:42–46.CrossRefPubMed
55.
go back to reference Kaminski MF, Regula J, Kraszewska E, Polkowski M, et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med. 2010;362:1795–1803.CrossRefPubMed Kaminski MF, Regula J, Kraszewska E, Polkowski M, et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med. 2010;362:1795–1803.CrossRefPubMed
56.
57.
go back to reference Bampton PA, Sandford J, Cole SR, Smith A, et al. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology. Gut. 2005;54:803–806.CrossRefPubMedCentralPubMed Bampton PA, Sandford J, Cole SR, Smith A, et al. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology. Gut. 2005;54:803–806.CrossRefPubMedCentralPubMed
58.
go back to reference Burnett-Hartman AN, Newcomb P, Phipps AI, Passarelli MN, Grady WM. Colorectal endoscopy, advanced adenomas, and sessile serrated polyps: implications for proximal colon cancer. Am J Gastroenterol. 2012;107:1213–1219.CrossRefPubMedCentralPubMed Burnett-Hartman AN, Newcomb P, Phipps AI, Passarelli MN, Grady WM. Colorectal endoscopy, advanced adenomas, and sessile serrated polyps: implications for proximal colon cancer. Am J Gastroenterol. 2012;107:1213–1219.CrossRefPubMedCentralPubMed
59.
go back to reference Lebwohl B, Kastrinos F, Glick M, Rosenbaum AJ, et al. The impact of suboptimal bowel preparation on adenoma miss rates and the factors associated with early repeat colonoscopy. Gastrointest Endosc. 2011;73:1207–1214.CrossRefPubMedCentralPubMed Lebwohl B, Kastrinos F, Glick M, Rosenbaum AJ, et al. The impact of suboptimal bowel preparation on adenoma miss rates and the factors associated with early repeat colonoscopy. Gastrointest Endosc. 2011;73:1207–1214.CrossRefPubMedCentralPubMed
60.
go back to reference Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US multi-society task force on colorectal cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58:130–160. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US multi-society task force on colorectal cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58:130–160.
61.
go back to reference Ahlquist DA, Sargent D, Loprinzi CL, Goldberg RM, et al. False-positive stool DNA results on colorectal cancer screening: yield from supracolonic evaluation. Gastroenterology. 2004;126:A-58. Ahlquist DA, Sargent D, Loprinzi CL, Goldberg RM, et al. False-positive stool DNA results on colorectal cancer screening: yield from supracolonic evaluation. Gastroenterology. 2004;126:A-58.
62.
go back to reference Jess T, Loftus E Jr, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population based study from Olmsted county, Minnesota. Gastroenterology. 2006;130:1039–1046.CrossRefPubMed Jess T, Loftus E Jr, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population based study from Olmsted county, Minnesota. Gastroenterology. 2006;130:1039–1046.CrossRefPubMed
63.
go back to reference Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology. 2004;126:1634–1648.CrossRefPubMed Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology. 2004;126:1634–1648.CrossRefPubMed
64.
go back to reference Farraye FA, Odze R, Eaden J, Itzkowitz SH, Harpaz N. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:746–774.CrossRefPubMed Farraye FA, Odze R, Eaden J, Itzkowitz SH, Harpaz N. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:746–774.CrossRefPubMed
65.
go back to reference Subramanian V, Mannath J, Ragunath K, Hawkey CJ. Meta-analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease. Ailment Pharmacol Ther. 2011;33:304–312.CrossRef Subramanian V, Mannath J, Ragunath K, Hawkey CJ. Meta-analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease. Ailment Pharmacol Ther. 2011;33:304–312.CrossRef
66.
go back to reference Karlen P, Kornfeld D, Brostrom O, Lofberg R, Persson PG, Ekbom A. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut. 1998;42:711–714.CrossRefPubMedCentralPubMed Karlen P, Kornfeld D, Brostrom O, Lofberg R, Persson PG, Ekbom A. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut. 1998;42:711–714.CrossRefPubMedCentralPubMed
67.
go back to reference Velayos FS, Liu L, Lewis JD, et al. Prevalence of colorectal cancer surveillance for ulcerative colitis in an integrated health care delivery system. Gastroenterology. 2010;139:1511–1518.CrossRefPubMed Velayos FS, Liu L, Lewis JD, et al. Prevalence of colorectal cancer surveillance for ulcerative colitis in an integrated health care delivery system. Gastroenterology. 2010;139:1511–1518.CrossRefPubMed
68.
go back to reference Kisiel JB, Yab T, Hussain FTH, Taylor WR, et al. Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:546–554.CrossRefPubMed Kisiel JB, Yab T, Hussain FTH, Taylor WR, et al. Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:546–554.CrossRefPubMed
69.
70.
go back to reference Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomark Prev. 2010;19:1893–1907.CrossRef Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomark Prev. 2010;19:1893–1907.CrossRef
71.
go back to reference Rahib L, Smith B, Aizenberg R, Rosenzweigh AB, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–2921.CrossRefPubMed Rahib L, Smith B, Aizenberg R, Rosenzweigh AB, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–2921.CrossRefPubMed
72.
go back to reference Ahlquist DA. Next-generation stool DNA testing: expanding the scope. Gastroenterology. 2009;136:2068–2073.CrossRefPubMed Ahlquist DA. Next-generation stool DNA testing: expanding the scope. Gastroenterology. 2009;136:2068–2073.CrossRefPubMed
73.
go back to reference Kisiel JB, Yab TC, Taylor WR, Chari ST, et al. Stool DNA testing for the detection of pancreatic cancer: assessment of methylation marker candidates. Cancer. 2012;118:2623–2631.CrossRefPubMedCentralPubMed Kisiel JB, Yab TC, Taylor WR, Chari ST, et al. Stool DNA testing for the detection of pancreatic cancer: assessment of methylation marker candidates. Cancer. 2012;118:2623–2631.CrossRefPubMedCentralPubMed
74.
go back to reference Strauss BB, Yab TC, OConnor HM, Taylor WR, et al. Fecal recovery of ingested cellular DNA: implications for noninvasive detection of upper gastrointestinal neoplasms. Gastroenterology. 2014;146:S-323–S-4. Strauss BB, Yab TC, OConnor HM, Taylor WR, et al. Fecal recovery of ingested cellular DNA: implications for noninvasive detection of upper gastrointestinal neoplasms. Gastroenterology. 2014;146:S-323–S-4.
75.
go back to reference Kisiel JB, Taylor WR, Yab TC, Mahoney DW, et al. Novel methylated DNA markers predict site of gastrointestinal cancer. Gastroenterology. 2013;144:S-84. Kisiel JB, Taylor WR, Yab TC, Mahoney DW, et al. Novel methylated DNA markers predict site of gastrointestinal cancer. Gastroenterology. 2013;144:S-84.
Metadata
Title
Multi-Target Stool DNA Test: A New High Bar for Noninvasive Screening
Author
David A. Ahlquist
Publication date
01-03-2015
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 3/2015
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-014-3451-5

Other articles of this Issue 3/2015

Digestive Diseases and Sciences 3/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.